Efficacy of bovine herpesvirus-1 inactivated vaccine against abortion and stillbirth in pregnant heifers
| Autor: | Christopher C. L. Chase, Louis G. Luempert, Robin E. Buterbaugh, Alicia D. Zimmerman, Jamie M. Hass, Nicole E. Frank, John M. Herbert |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Abortion Vaccines Attenuated law.invention Randomized controlled trial Pregnancy law medicine Animals Prospective Studies Pregnancy Complications Infectious Prospective cohort study Fetal Death Infectious Bovine Rhinotracheitis Herpesvirus 1 Bovine Gynecology General Veterinary biology Obstetrics business.industry Viral Vaccine Vaccination Viral Vaccines Abortion Veterinary biology.organism_classification medicine.disease Bovine herpesvirus 1 Vaccines Inactivated Inactivated vaccine Cattle Female business |
| Zdroj: | Journal of the American Veterinary Medical Association. 231:1386-1389 |
| ISSN: | 0003-1488 |
| DOI: | 10.2460/javma.231.9.1386 |
| Popis: | Objective—To evaluate the efficacy of an inactivated bovine herpesvirus-1 (BHV-1) vaccine to protect against BHV-1 challenge-induced abortion and stillbirth. Design—Prospective study. Animals—35 beef heifers. Procedures—Before breeding, heifers were vaccinated with a commercially available BHV-1 inactivated vaccine SC or IM. The estrous cycle was then synchronized, and heifers were artificially inseminated 30 to 60 days after vaccination. Heifers (n = 21) were challenge inoculated IV at approximately 180 days of gestation with virulent BHV-1. Fourteen control heifers were not vaccinated. Clinical signs of BHV-1 infection were monitored for 10 days following challenge; serologic status and occurrence of abortion or stillbirth were evaluated until time of calving. Results—18 of 21 (85.7%) heifers that received vaccine were protected from abortion following challenge, whereas all 14 control heifers aborted. Conclusions and Clinical Relevance—Results indicated that an inactivated BHV-1 vaccine can protect against abortion resulting from a substantial challenge infection, with efficacy similar to that of modified-live BHV-1 vaccines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|